SEARCH

SEARCH BY CITATION

References

  • 1
    Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133(6 Suppl.): 381S453S.
  • 2
    Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133(6 Suppl.): 160S98S.
  • 3
    Agnelli G, Eriksson BI, Cohen AT et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 88497.
  • 4
    Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 157380.
  • 5
    Eriksson BI, Dahl OE, Büller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 6
    Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 94956.
  • 7
    Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 217885.
  • 8
    RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 19.
  • 9
    Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 10
    Turpie AG, Fisher WD, Bauer KA et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 247986.
  • 11
    Eriksson BI, Borris L, Dahl OE et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 1218.
  • 12
    Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 276575.
  • 13
    Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 319.
  • 14
    Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 277686.
  • 15
    Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 167380.
  • 16
    Buller HR, Lensing AW, Prins MH et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 22427.
  • 17
    Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 236875.
  • 18
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594604.
  • 19
    Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 13138.
  • 20
    Stangier J, Eriksson BI, Dahl OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy subjects and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 55563.
  • 21
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 54958.
  • 22
    US Department of Health and Human Services. Briefing Information for the March 19, 2009 Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm138368.htm (accessed August 2009).
  • 23
    Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 221121.
  • 24
    Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 6774.
  • 25
    Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 38699.
  • 26
    Pradaxa® (dabigatran etexilate). Summary of product characteristics, last updated 03/2009. Boehringer Ingelheim International GmbH. http://www.pradaxa.com/Include/media/pdf/Pradaxa_SPC_EMEA.pdf (accessed August 2009).
  • 27
    Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007; 12: 83843.
  • 28
    Xarelto® (rivaroxaban). Summary of product characteristics, last updated 09/2008. Bayer Schering Pharma. http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf (accessed August 2009).
  • 29
    Zhang D, He K, Raghavan N et al. Comparative metabolism of 14C labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009; 37: 173848.
  • 30
    He K, He B, Grace JE et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor [abstract]. Blood 2006; 108: abstract 910.
  • 31
    Gaikwad R, Sketris IS, Shepherd M, Duffy J (2006) Evaluation of accuracy of drug interaction alerts triggered by two electronic medical record systems in primary health care. In: AbidiR, BathP, KeseljV, eds. ISHIMR 2006 – Advancing Health Information Management and Health Informatics: Issues, Strategies, and Tools. Proceedings of the 11th International Symposium on Health Information Management Research. Halifax, Nova Scotia, Canada July 14–16.
  • 32
    Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9: 5968.
  • 33
    Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and atorvastatin. Poster P062 presented at the 20th International Congress on Thrombosis (ICT), Athens, Greece; 25–28 June 2008. http://www.xarelto.com/html/images/events/ICT/ICT_2008_Atorvastatin_Interaction.pdf.
  • 34
    Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract]. J Thromb Haemost 2007; 5(S2): abstract P-W-672.
  • 35
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin. J Clin Pharmacol 2006; 46: 98190.
  • 36
    Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 141926.
  • 37
    Eriksson BI, Turpie AG, Lassen MR et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effects of specified co-medications. Abstract 1986 presented at the American Society of Hematology (ASH) 50th Annual Meeting and Exposition, San Francisco, CA; December 6–9, 2008. http://www.xarelto.com/html/images/events/ASH/ASH2008_Pooled_Analysis_of_Four_Pivotal_Studies_of_Rivaroxaban.pdf (accessed December 2009).
  • 38
    Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 2938.
  • 39
    Perzborn E, Fischer E, Lange U. Concomitant administration of rivaroxaban – an oral, direct Factor Xa inhibitor – with clopidogrel and acetylsalicylic acid enhances antithrombosis in rats. Poster P060 presented at the 20th International Congress on Thrombosis (ICT), Athens, Greece; 25–28 June 2008. http://www.xarelto.com/html/images/events/ICT/ICT_2008_Interaction_with_Clopidogrel_and_Acetylsalicylic_Acid.pdf (accessed December 2009).
  • 40
    Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008; 6: 173641.
  • 41
    APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 287785.
  • 42
    Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract]. J Thromb Haemost 2007; 5(S2): abstract P-T-677.
  • 43
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 46976.
  • 44
    Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 4759.
  • 45
    Masood S, Cunanan J, Hoppensteadt D, Van Thiel D, Fareed J. Drug interactions of oral antithrombin and anti-Xa agents with heparinized and oral anticoagulant treated patients [abstract]. J Thromb Haemost 2009; 7(S2): abstract PP-TH-142.
  • 46
    Frost CE, Yu Z, Wang J et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 2009; 85(Suppl. 1): S34.
  • 47
    Masood S, Van Thiel D, George M, Hoppensteadt D, Fareed J. Differential augmentation of the anticoagulant responses by newly developed oral anti-Xa and anti-IIa drugs in patients with liver disease [abstract]. FASEB J 2009; 23(Suppl.): abstract LB383.
  • 48
    Halabi A, Maatouk H, Klause N et al. Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct, factor Xa inhibitor [abstract]. Blood 2006; 108: abstract 913.
  • 49
    Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 20316.
  • 50
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 286778.
  • 51
    Aspirin Foundation. Homepage. http://www.aspirin-foundation.com/index.html (accessed August 2009).
  • 52
    Magro L, Conforti A, Del Zotti F et al. Identification of severe potential drug-drug interactions using an Italian general-practitioner database. Eur J Clin Pharmacol 2008; 64: 3039.
  • 53
    Turunen JH, Mäntyselkä PT, Kumpusalo EA, Ahonen RS. Frequent analgesic use at population level: prevalence and patterns of use. Pain 2005; 115: 37481.
  • 54
    Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. Am Heart J 2008; 155: 9049.
  • 55
    Tipples K, Robinson A. Optimising care of elderly breast cancer patients: a challenging priority. Clin Oncol (R Coll Radiol) 2009; 21: 11830.
  • 56
    Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olsen RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004; 164: 22605.
  • 57
    Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009; 54: 95109.
  • 58
    Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38: 84353.
  • 59
    Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21181.
  • 60
    Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 23705.
  • 61
    Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008; 22: 7718.
  • 62
    Goldstein KM, Gluckman S, Mounzer K. Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. AIDS Read 2008; 18: 4802; 486–9.
  • 63
    Centers for Disease Control and Prevention (CDC). Prevalence of self-reported epilepsy – United States, 1986–1990. MMWR Morb Mortal Wkly Rep 1994; 43: 8101; 817–8.
  • 64
    Shaikh U, Byrd RS, Auinger P. Vitamin and mineral supplement use by children and adolescents in the 1999-2004 National Health and Nutrition Examination Survey: relationship with nutrition, food security, physical activity, and health care access. Arch Pediatr Adolesc Med 2009; 163: 1507.
  • 65
    Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol 2000; 3: 2432.
  • 66
    Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol. 2006; 1: 15761.
  • 67
    Marsh SA, Coombes JS. Vitamin E and alpha-lipoic acid supplementation increase bleeding tendency via an intrinsic coagulation pathway. Clin Appl Thromb Hemost 2006; 12: 16973.
  • 68
    Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des 2008; 14: 172342.
  • 69
    Heard KJ, Ries NL, Dart RC, Bogdan GM, Zallen RD, Daly F. Overuse of non-prescription analgesics by dental clinic patients. BMC Oral Health 2008; 8: 33.
  • 70
    Gandhi TK, Weingart SN, Seger AC et al. Outpatient prescribing errors and the impact of computerized prescribing. J Gen Intern Med 2005; 20: 83741.
  • 71
    Wolf MS, Davis TC, Shrank W et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 2007; 67: 293300.
  • 72
    Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29(Suppl.): 247797.
  • 73
    Eriksson BI, Borris LC, Dahl OE et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 237481.